Loading...
Loading...
Browse all stories on DeepNewz
VisitFDA Places Clinical Hold on Novavax's COVID-19 and Influenza Vaccines Due to Safety Concerns in Phase 3 Trial
Oct 16, 2024, 12:13 PM
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Novavax's COVID-19 and influenza combination vaccine, as well as its standalone influenza vaccine candidates due to safety concerns. This decision comes after a spontaneous report of a serious adverse event (SAE) involving motor neuropathy. The clinical hold affects the Investigational New Drug (IND) applications for these vaccines, which were in Phase 3 Trial.
View original story
Markets
Yes • 50%
No • 50%
FDA official announcements or press releases
No • 50%
Yes • 50%
Novavax official announcements or press releases
No • 50%
Yes • 50%
FDA official announcements or press releases
Remains within 10% of current value • 25%
Other outcome • 25%
Increases by 10% or more • 25%
Decreases by 10% or more • 25%
Stock market data from financial news outlets
Continue with current strategy • 25%
Partnership with another company • 25%
Other strategic response • 25%
Focus on different vaccine candidates • 25%
Novavax official announcements or press releases
Other outcome • 25%
Safety concerns resolved • 25%
Further investigation required • 25%
Vaccine trials permanently halted • 25%
FDA official announcements or press releases